Quanterix (NASDAQ: QTRX) reported Q1 EPS of $, versus ($0.27) reported last year. Revenue for the quarter came in at $7.5 million versus the consensus estimate of $7.11 million.

“The first full quarter following the successful close of our initial public offering marked an important milestone in our transition as a public company, particularly as we continue our focus on growing revenues and transforming biomarker detection by enabling non-invasive, ultra-sensitive measurement of molecular biomarkers,” said Chief Executive Officer, President and Chairman, Kevin Hrusovsky. “We are pleased with our strong first quarter performance and enthusiastic about the market opportunity in front of us, particularly in research markets for improving drug development with biomarkers and pharma services in the short to mid-term and in diagnostics and precision health screens in the long term.”

First Quarter 2018 Financial Highlights

Key financial results for the first quarter are shown below:

• Q1 revenue of $7.5M versus prior year Q1 of $5.3M, an increase of 41%.
• Q1 product revenue was $4.7M versus prior year Q1 of $3.4M, an increase of 38%.
• Q1 Service and Other revenue totaled $2.5M versus prior year Q1 of $1.6M, an increase of 52%.

For earnings history and earnings-related data on Quanterix (QTRX) click here.